PNC-27

Overview

An experimental p53-derived peptide studied for selective membrane disruption of cancer cells. Strictly preclinical; no approved or validated human use.

Mechanism of Action

Contains an HDM-2-binding p53 domain fused to a membrane-residency peptide; reported to form transmembrane pores selectively in cancer cells in vitro.

Research Summary

In-vitro and limited animal studies from a small number of labs; results are not independently established and there are no human trials.

Vendors selling PNC-27

Scored vendors carrying PNC-27, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Unknown in humans

Frequently asked questions

Has PNC-27 been independently lab-tested?

Disclosed Labs has collected 6 Certificates of Analysis (COA) for PNC-27 from 5 independent testing labs. 4 vendors have submitted material for testing. Products average 99.6% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/pnc-27/testing.

What is the average purity of PNC-27 on the market?

Based on 6 COAs analyzed by Disclosed Labs, PNC-27 products average 99.6% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/pnc-27/coas.

Where can researchers source PNC-27?

3 vendors with Disclosed Labs trust grades currently list PNC-27, including Ion Peptide, Peptidology, BioLongevity Labs. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/pnc-27.

How does PNC-27 work?

Contains an HDM-2-binding p53 domain fused to a membrane-residency peptide; reported to form transmembrane pores selectively in cancer cells in vitro.

What does the research say about PNC-27?

In-vitro and limited animal studies from a small number of labs; results are not independently established and there are no human trials.